Moomoo AI 已提取核心信息
Adial Pharmaceuticals, Inc. (Adial), a Delaware-based pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on January 12, 2024. The registration statement, identified as Form S-3, includes a prospectus for the potential sale of various securities, which may comprise common stock, preferred stock, debt securities, warrants, and units. The company has not specified the total amount of securities to be offered or the timing of any sales, indicating that offerings will occur from time to time based on market conditions. The registration statement outlines the terms under which the securities may be offered, the use of proceeds, and the company's indemnification obligations to directors and officers. Adial has made provisions for the securities to be sold through underwriters, dealers, or directly to the public, with the possibility of book-entry or global securities issuance. The registration statement also includes financial statements audited by Marcum LLP and legal opinions by Blank Rome LLP.
Adial Pharmaceuticals, Inc. (Adial), a Delaware-based pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on January 12, 2024. The registration statement, identified as Form S-3, includes a prospectus for the potential sale of various securities, which may comprise common stock, preferred stock, debt securities, warrants, and units. The company has not specified the total amount of securities to be offered or the timing of any sales, indicating that offerings will occur from time to time based on market conditions. The registration statement outlines the terms under which the securities may be offered, the use of proceeds, and the company's indemnification obligations to directors and officers. Adial has made provisions for the securities to be sold through underwriters, dealers, or directly to the public, with the possibility of book-entry or global securities issuance. The registration statement also includes financial statements audited by Marcum LLP and legal opinions by Blank Rome LLP.
总部位于特拉华州的制药公司阿迪亚尔制药公司（Adial）已于2024年1月12日向美国证券交易委员会（SEC）提交了注册声明。注册声明名为S-3表格，包括可能出售各种证券的招股说明书，这些证券可能包括普通股、优先股、债务证券、认股权证和单位。该公司没有具体说明要发行的证券总额或任何出售的时间，这表明将根据市场状况不时进行发行。注册声明概述了证券发行的条款、所得款项的使用以及公司对董事和高级管理人员的赔偿义务。Adial已规定证券可以通过承销商、交易商或直接向公众出售，并有可能进行账面记账或全球证券发行。注册声明还包括由Marcum LLP审计的财务报表和Blank Rome LLP的法律意见。
总部位于特拉华州的制药公司阿迪亚尔制药公司（Adial）已于2024年1月12日向美国证券交易委员会（SEC）提交了注册声明。注册声明名为S-3表格，包括可能出售各种证券的招股说明书，这些证券可能包括普通股、优先股、债务证券、认股权证和单位。该公司没有具体说明要发行的证券总额或任何出售的时间，这表明将根据市场状况不时进行发行。注册声明概述了证券发行的条款、所得款项的使用以及公司对董事和高级管理人员的赔偿义务。Adial已规定证券可以通过承销商、交易商或直接向公众出售，并有可能进行账面记账或全球证券发行。注册声明还包括由Marcum LLP审计的财务报表和Blank Rome LLP的法律意见。
有用
没用